Xeomin was recently approved for in the United States, making it the latest botulinum toxin to achieve FDA approval. This product may be the one that drives pricing to a more favorable position for patients, making botulinum toxin injections much more accessible.
Xeomin has been used in Germany since 2008. It is essentially the same product as Botox, just without the additives. This makes the product extremely easy to use for patients and physicians. The theoretic advantage of Xeomin is that with less additives, there is less likelihood of developing antibody formation with continued use.
Botox is an excellent product. However, it is good news for the consumer when more botulinum toxins are approved to help drive prices down and make these products available.
Dr. Shah offers Xeomin treatments in his Chicago office.